L & S Advisors’s IGM Biosciences IGMS Stock Holding History

L & S Advisors’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,000	Closed	-$230K	–	351
2021 Q1	$230K	Sell	3,000 -3,000	-50%	-$273K	0.03%	321
2020 Q4	$530K	Buy	+6,000	New	+$422K	0.06%	243

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

L & S Advisors's IGMS Position: Q2 2021 in Review

L & S Advisors sold out of IGM Biosciences (IGMS) in Q2 2021, closing a stake of 3,000 shares — an estimated $230K sold.

L & S Advisors first reported a position in IGMS in Q4 2020 and held it in 2 quarters. The position peaked at $530K in Q4 2020. 104 funds tracked by Wall St. Rank hold IGMS as of Q2 2021.

L & S Advisors reported no remaining IGM Biosciences position as of Q2 2021 after selling out during the quarter.
L & S Advisors sold 3,000 IGM Biosciences shares in Q2 2021, an estimated $230K.
L & S Advisors first reported a position in IGM Biosciences in Q4 2020 and held it in 2 quarters.
L & S Advisors's IGM Biosciences position peaked at $530K in Q4 2020.
104 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2021.

Based on L & S Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.